# Exploring the genomic and transcriptomic profiles of glycemic traits and drug repurposing

**Authors:** Min-Rou Lin, Cheng-Lin Tsai, Cai-Sian Liao, Chun-Yu Wei, Wan-Hsuan Chou, Tzu-Hung Hsiao, Wei-Chiao Chang

PMC · DOI: 10.1186/s12929-025-01137-7 · Journal of Biomedical Science · 2025-05-21

## TL;DR

This study explores the genetic and transcriptomic factors influencing blood sugar levels in a Taiwanese population and identifies potential repurposed drugs for treating type 2 diabetes.

## Contribution

The study provides new genetic insights and drug repurposing opportunities specific to the Taiwanese Han population for glycemic traits.

## Key findings

- New genes MAEA and PRC1 were discovered to be associated with glycemic traits.
- Eight repurposed drugs were identified that may regulate blood glucose levels.
- A higher polygenic risk score was linked to an increased risk of type 2 diabetes.

## Abstract

Type 2 diabetes is an increasingly prevalent metabolic disorder with moderate to high heritability. Glycemic indices are crucial for diagnosing and monitoring the disease. Previous genome-wide association study (GWAS) have identified several risk loci associated with type 2 diabetes, but data from the Taiwanese population remain relatively sparse and primarily focus on type 2 diabetes status rather than glycemic trait levels.

We conducted a comprehensive genome-wide meta-analysis to explore the genetics of glycemic traits. The study incorporated a community-based cohort of 145,468 individuals and a hospital-based cohort of 35,395 individuals. The study integrated genetics, transcriptomics, biological pathway analyses, polygenic risk score calculation, and drug repurposing for type 2 diabetes.

This study assessed hemoglobin A1c and fasting glucose levels, validating known loci (FN3K, SPC25, MTNR1B, and FOXA2) and discovering new genes, including MAEA and PRC1. Additionally, we found that diabetes, blood lipids, and liver- and kidney-related traits share genetic foundations with glycemic traits. A higher PRS was associated with an increased risk of type 2 diabetes. Finally, eight repurposed drugs were identified with evidence to regulate blood glucose levels, offering new avenues for the management and treatment of type 2 diabetes.

This research illuminates the unique genetic landscape of glucose regulation in Taiwanese Han population, providing valuable insights to guide future treatment strategies for type 2 diabetes.

The online version contains supplementary material available at 10.1186/s12929-025-01137-7.

## Linked entities

- **Genes:** FN3K (fructosamine 3 kinase) [NCBI Gene 64122], SPC25 (SPC25 component of NDC80 kinetochore complex) [NCBI Gene 57405], MTNR1B (melatonin receptor 1B) [NCBI Gene 4544], FOXA2 (forkhead box A2) [NCBI Gene 3170], MAEA (macrophage erythroblast attacher, E3 ubiquitin ligase) [NCBI Gene 10296], PRC1 (protein regulator of cytokinesis 1) [NCBI Gene 9055]
- **Diseases:** type 2 diabetes (MONDO:0005148)

## Full-text entities

- **Diseases:** Type 2 diabetes (MESH:D003924), metabolic disorder (MESH:D008659), diabetes (MESH:D003920)
- **Chemicals:** A1c (-), blood glucose (MESH:D001786), glucose (MESH:D005947)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12096723/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12096723/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12096723/full.md

---
Source: https://tomesphere.com/paper/PMC12096723